PROOF Centre, AstraZeneca Partner on Chronic Kidney Disease Test
With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.
HTG Validating PROOF Centre's Heart Transplant Rejection Assay
NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.
Canada's Prevention of Organ Failure Centre of Excellence has granted HTG Molecular Diagnostics exclusive rights to commercialize a risk stratification test the center has been developing to better personalize treatment for chronic obstructive pulmonary disease.
HTG Molecular Dx Licenses PROOF Centre COPD Testing Tech
NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics said today that it has licensed exclusive rights from Vancouver's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) to commercialize gene expression tests for prognosis of COPD patients who will experience frequent lung a
PROOF, IO Informatics to Develop App Aimed at Heart, Lung, and Kidney Disease
NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure, or PROOF Centre, and IO Informatics today announced a deal to develop a web-based software application addressing chronic heart, lung, and kidney disease.
Apr 6, 2010
Luminex, Proof Centre Team on Transplant Tests
Feb 18, 2009